All the essential ingredients to make the DNA and RNA underpinning life on Earth have been discovered in samples collected from the asteroid Ryugu, scientists said Monday.
The discovery comes after these building blocks of life were detected on another asteroid called Bennu, suggesting they are abundant throughout the solar system.
One longstanding theory is that life first began on Earth when asteroids carrying fundamental elements crashed into our planet long ago.
Cerebral blood flow is essential for normal brain function and often perturbed in neurological disease. If one shines a source of coherent light on perfused tissue, the detected speckles, or “grains” of light fluctuate, or “dance,” at a rate proportional to blood flow in the volume sampled by the light. In brain tissue, this concept can be harnessed to measure the cerebral blood flow index (CBFi).
However, to date, implementations of this principle for noninvasive adult human brain monitoring—collectively known as diffuse correlation spectroscopy (DCS)—have achieved limited brain sensitivity. This is because the brain is 1–2 centimeters deep beneath the scalp and skull, meaning that the light must sample the superficial tissue before reaching the brain.
While the collection points can be moved further from the source to address this issue by improving sampling of the brain, this strategy requires many photon-counting channels to detect highly attenuated light far from the source. DCS becomes prohibitively expensive as the number of channels increases.
Researchers at the University of California, Irvine, Israel’s Tel Aviv University and other institutions have developed a first-of-its-kind membrane through which charged molecules pass using nothing more than a rapidly switching low-voltage signal. This “ratchet-based ion pump” has no moving parts and requires no chemical reactions.
The device opens the door to advances in water desalination, lithium ion harvesting from seawater, heavy-metal removal from drinking water, battery recycling and various biomedical applications. The team’s findings are outlined in a paper published recently in Nature Materials.
Biobots, whose growing line of variants started with xenobots, are fascinating tiny self-powered living robots built exclusively using frog embryonic cells. Originally developed in the laboratories of Wyss Institute Associate Faculty member and Tufts University Professor Michael Levin, Ph.D. and his collaborators at University of Vermont, biobots are remarkably motile, moving autonomously through aqueous environments.
Since then, the team has shed light on many exciting properties of biobots, including their ability for kinematic self-replication, and responding to sound stimuli.
Biobots can similarly be constructed using human cells in the form of anthrobots, which have the ability to heal neural wounds in vitro. Thus, a vision emerged that biobots, made out of patients’ own cells, could one day be deployed to repair spinal cord or retinal nerve damage, clear plaques from the arteries, locally deliver pro-regenerative drugs, and perform other vital tasks in the human body.
Last week’s cyberattack on medical technology giant Stryker was limited to its internal Microsoft environment and remotely wiped tens of thousands of employee devices.
The organization says in an update on Sunday that all its medical devices are safe to use but electronic ordering systems remain offline, and customers must place orders manually through sales representatives.
Stryker emphasizes that the incident was not a ransomware attack and that the threat actor did not deploy any malware on its systems.
Online now: Jia et al. delineate the most comprehensive plasma proteomic landscape of frailty to date and develop proteomic frailty scores that predict multiple diseases and respond to modifiable risk factors. They identify a biphasic pattern of frailty-related proteomic alterations across the lifespan, revealing critical windows that may inform targeted intervention programs.
This study demonstrates that the FDA-approved drug 18AA potently resensitizes multidrug-resistant pathogens to ceftazidime-avibactam. It achieves this by activating two bacterial pathways, the inosine-CusS/R-CusC axis and the proton motive force, to promote antibiotic influx, offering a readily translatable strategy against formidable infections.
“When engineering a computer, you need to know the circuitry of the central processing unit. If you don’t know how everything is wired together, you can’t understand its function, optimize it or fix it when something breaks. We are approaching the brain the same way,” said study leader Boxuan Zhao, a professor of cell and developmental biology at the University of Illinois Urbana-Champaign.
“Our technology enables simultaneous mapping of thousands of neural connections with single-synapse resolution —a capability that doesn’t exist in any current technology. It is directly applicable to understanding circuit dysfunction in neurodegenerative diseases and could provide a platform for developing circuit-guided therapeutic interventions,” he said.
In this Research Article, Ruxandra Bachmann-Gagescu & team integrate blood and urine biochemistry with genetics to improve interpretation of genetic findings in adults with kidney stone disease—the approach has prognostic value, enabling personalized risk assessment.
3Department of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
4National Center of Competence in Research (NCCR) Kidney. CH, Bern, Switzerland.
5Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
ADJUVANT: Testing if IV tirofiban is non-inferior to thrombolysis before endovascular thrombectomy for acute ischemic stroke. Read about the upcoming trial.
BackgroundIntravenous thrombolysis followed by endovascular thrombectomy (EVT) is a first‐line recommended strategy for thrombolysis‐eligible patients with stroke due to acute large‐vessel occlusion. Tirofiban, one of the most used glycoprotein IIb/IIIa receptor inhibitors, has been increasingly advocated to counteract different stages of thrombosis mediated by activated platelets. It is unclear whether tirofiban could be used as an alternative to thrombolysis as adjuvant medicine for EVT. This trial aims to assess whether intravenous tirofiban plus EVT is noninferior to intravenous thrombolysis bridging with EVT in patients with acute ischemic stroke due to large‐vessel occlusion who are eligible for thrombolysis.